While these observations suggest that liraglutide attenuates inflammation and fibrosis, which are key mediators of diabetic cardiomyopathy consistent with the actions of GLP-1R agonists in the setting of ischemic heart disease and heart failure (Ussher and Drucker, 2014; Drucker, 2016), it should be noted that diastolic function was not assessed in this particular study. Here, GLP1R is linked to diabetic cardiomyopathy.